After a confirmed pancreatitis while on tirzepatide, what is the most appropriate action?

After a confirmed pancreatitis while on tirzepatide, what is the most appropriate action?

• A. Do not restart tirzepatide
• B. Restart tirzepatide at lower dose
• C. Continue with current dose
• D. Restart only after symptoms resolve

Answer: (A)

Pancreatitis is a serious adverse event seen with incretin-based therapies, including tirzepatide. If pancreatitis is confirmed in a patient taking tirzepatide, the drug should be permanently discontinued and not rechallenged. Reintroducing tirzepatide could trigger another pancreatitis episode, with the risk outweighing any potential benefit. After resolution, choose alternative diabetes or weight-management options that do not involve tirzepatide. This is why stopping without restarting is the most appropriate action.

Pancreatitis is a serious adverse event seen with incretin-based therapies, including tirzepatide. If pancreatitis is confirmed in a patient taking tirzepatide, the drug should be permanently discontinued and not rechallenged. Reintroducing tirzepatide could trigger another pancreatitis episode, with the risk outweighing any potential benefit. After resolution, choose alternative diabetes or weight-management options that do not involve tirzepatide. This is why stopping without restarting is the most appropriate action.